The rs2147578C > G polymorphism in the Inc-LAMC2–1:1 gene is associated with increased neuroblastoma risk in the Henan children

The rs2147578C > G polymorphism in the Inc-LAMC2–1:1 gene is associated with increased... Background: The rs2147578 C > G polymorphism in the long non-coding RNA gene Lnc-LAMC2–1:1 is associated with increased susceptibility to a few types of cancers. However, its role in neuroblastoma has not been evaluated yet. Methods: We investigated the association between the lnc-LAMC2–1:1 rs2147578 C > G polymorphism and neuroblastoma susceptibility in Chinese Han populations. A total of 393 neuroblastoma cases and 812 healthy individuals from the Henan and Guangdong provinces were enrolled and subjected to genotyping. Odds ratio (OR) and 95% confidence interval (CI) were used to determine the strength of the association of interest. Results: Combined analysis revealed that the lnc-LAMC2–1:1 rs2147578 C > G polymorphism was associated with increased neuroblastoma susceptibility (CG vs. CC: adjusted OR = 1.33, 95% CI = 1.01–1.75, P = 0.045; CG/GG vs. CC: adjusted OR = 1.34, 95% CI = 1.03–1.74, P = 0.028). In stratification analysis, children under 18 months with rs2147578 CG/GG genotypes had an increased neuroblastoma risk (adjusted OR = 1.70, 95% CI = 1.08–2.67, P = 0.022). Females with rs2147578 CG/GG genotypes also had increased neuroblastoma susceptibility (adjusted OR = 2.08, 95% CI = 1.37– 3.18, P = 0.0007). In addition, children with lnc-LAMC2–1:1 rs2147578 CG/GG genotypes were prone to develop earlier stages of neuroblastoma (adjusted OR = 1.46, 95% CI = 1.01–2.12, P =0.046). Conclusions: The Lnc-LAMC2–1:1 rs2147578 C > G polymorphism may contribute to increased neuroblastoma susceptibility in children of Henan province. Keywords: rs2147578, Neuroblastoma, Long non-coding RNA, Polymorphism Background stage, N-myc status, DNA ploidy, and structural chromo- Neuroblastoma is the most common malignant extracranial somal aberrations [3–5]. solid tumor in children, accounting for 7–10% of all tumors Genetic factors are critically important in neuroblast- [1, 2]. Neuroblastoma originates from neural crest precur- oma tumorigenesis. Approximately 1% of the patients sor cells of the sympathetic nervous system and is mainly have a family history of neuroblastoma, and are carriers of located in the adrenal medulla, paraspinal ganglia, and certain genetic mutations. For instance, anaplastic lymph- sympathetic trunk [3–5]. The outcome of neuroblastoma is oma kinase (ALK)and PHOX2B gene variants are among affected by several factors such as age of onset, pathological the predisposing factors to familial neuroblastoma [6–8]. subtype, International Neuroblastoma Staging System (INSS) Evidence of genome-wide association studies (GWASs) of sporadic cases also suggests that genetic factors may be in- * Correspondence: hejing198374@gmail.com; hejing@gwcmc.org; volved in the pathogenesis of neuroblastoma [9, 10]. These 378319696@qq.com; monknut@126.com 1 studies indicate an important role of genetic characteris- Department of Pediatric Surgery, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, 9 Jinsui Road, Guangzhou tics in the tumorigenesis of this disease. 510623, Guangdong, China Full list of author information is available at the end of the article © The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. Yang et al. BMC Cancer (2018) 18:948 Page 2 of 6 Long non-coding RNAs (lncRNAs) are mRNA-like their legal guardians for the use of their children’smedical molecules whose genes belong to the non-protein coding data and biological samples. genome. LncRNAs are involved in many biological pro- cesses such as gene imprinting, epigenetic regulation, SNP selection and genotyping translational regulation, splicing, and aging [11–15]. The Lnc-LAMC2–1:1 rs2147578 C > G polymorphism LncRNAs are also involved in apoptosis and cell differ- was genotyped using the TaqMan real-time PCR system entiation, which are critical in tumorigenesis [16, 17]. on a 7900 Sequence Detection System (Applied Biosys- LncRNAs such as HULC, PCAT-1, HOTAIR, ANRIL, tems, Foster City, CA), as described previously [29–31]. and H19 are found to play important roles in cancer de- Briefly, high-quality DNA samples were genotyped using velopment [17]. Single nucleotide polymorphism (SNP) Taqman real-time PCR method on a 7900 HT sequence at HULC is associated with decreased hepatocellular car- detector system. The call rate for the SNPs was 99%, cinoma risk [18]. GWAS show that neuroblastoma pa- which met the pre-set criterion. For quality control, tients with the G allele of SNP rs6939340, which is eight duplicate positive and eight negative controls with- located in the lncRNA LOC729177 gene, have a high out DNA were used in each 384-well plate [32, 33]. Add- risk of metastasis and poor outcome [19, 20]. These itionally, 10% samples were randomly selected and studies indicate that evaluation of lncRNA gene poly- repeated, and the reproducibility was 100% concordant. morphism would be of great value in the risk assessment of neuroblastoma. Statistical analysis The rs2147578 C > G polymorphism in the lncRNA All statistical tests were two-sided, with a significance gene Lnc-LAMC2–1:1 is associated with susceptibility to level of P < 0.05. All statistical analyses were performed several types of cancer, and functional polymorphism in using SAS software (Version 9.4; SAS Institute, Cary, lnc-LAMC2–1:1 may confer a high risk of colorectal NC, USA). Two-sided χ tests were used to analyze cancer through affecting miRNA binding [21]. Moreover, demographic data and genotype frequencies. The the lnc-LAMC2–1:1 rs2147578 polymorphism is also Hardy-Weinberg equilibrium was assessed using the considered a possible risk factor for acute lymphoblastic goodness-of-χ test. Odds ratios (OR) and 95% confi- leukemia (ALL) in children [22]. However, few studies dence intervals (CIs) were calculated using the Woolf have focused on this polymorphism in neuroblastoma. approximation method to evaluate association between Here we hypothesized that the lnc-LAMC2–1:1 rs214757 the lnc-LAMC2–1:1 rs2147578 C > G polymorphism and 8 C > G polymorphism may contribute to neuroblastoma neuroblastoma susceptibility. Crude and age- and susceptibility, and we tested our hypothesis via a gender-adjusted OR were evaluated using the uncondi- case-control study. tional logistic regression method. Results Materials and methods Demographic characteristics of the study population Study subjects A total of 275 cases of neuroblastoma and 531 health The subjects enrolled were described in previous studies controls in Guangdong province and 118 neuroblastoma [23, 24]. Briefly, 393 neuroblastoma patients and 812 cases and 281 health controls in Henan province were cancer-free controls were enrolled from two different prov- evaluated (Additional File 1 Table S1). Age and gender inces of China: 275 neuroblastoma patients and 531 controls distributions were similar between cases and controls in from the Guangzhou Women and Children’s Medical Cen- both Guangdong and Henan province subgroups (P > ter in Southern China, and 118 neuroblastoma patients and 0.05). Distribution of clinical stages and sites of tumor 281 controls from the Henan province in Northern China origin are also listed in Additional file 1 Table S1. [25, 26]. Diagnosis and clinical stages of neuroblastoma were assigned according to the Shimada system and the inter- Lnc-LAMC2–1:1 rs2147578 C > G polymorphism and national criteria for neuroblastoma staging system [27, 28]. susceptibility to neuroblastoma Healthy controls had no history of malignancies and were Genotype and allele frequencies of the lnc-LAMC2–1:1 matched to the neuroblastoma cases in terms of age rs2147578 C > G polymorphism and associations with (±5 years), gender, ethnicity, and geographical region. Both neuroblastoma risk are summarized in Table 1. In both cases and controls were unrelated Chinese Han individuals combined and subgroup analyses, the genotype distribu- living in the Guangdong and Henan provinces of China. tion of the lnc-LAMC2–1:1 rs2147578 C > G polymorph- This study was approved by the Institutional Review ism in the controls and cases were consistent with Board of Guangzhou Women and Children’sMedical Hardy-Weinberg equilibrium (P = 0.164 for combined Center (Guangzhou, China), and written informed con- subjects, P = 0.279 for Guangdong province, and sent was obtained from the parents of the participants or P = 0.386 for Henan province). Yang et al. BMC Cancer (2018) 18:948 Page 3 of 6 Table 1 Genotype distribution of the lnc-LAMC2–1:1 rs2147578 C > G polymorphism and neuroblastoma susceptibility a b Genotype Case Control P Crude OR P Adjusted OR P (95% CI) (95% CI) Guangdong province (HWE = 0.279) CC 88 (32.00) 195 (36.79) 1.00 1.00 CG 130 (47.27) 243 (45.85) 1.19 (0.85–1.65) 0.312 1.18 (0.85–1.64) 0.332 GG 57 (20.73) 92 (17.36) 1.37 (0.91–2.08) 0.135 1.38 (0.91–2.10) 0.127 Additive 0.305 1.17 (0.96–1.44) 0.124 1.18 (0.96–1.44) 0.120 Dominant 187 (68.00) 335 (63.21) 0.177 1.24 (0.91–1.68) 0.177 1.23 (0.91–1.68) 0.183 Recessive 218 (79.27) 438 (82.64) 0.243 1.25 (0.86–1.80) 0.244 1.26 (0.87–1.82) 0.223 Henan province (HWE = 0.386) CC 29 (24.58) 99 (35.36) 1.00 1.00 CG 67 (56.78) 129 (46.07) 1.77 (1.07–2.95) 0.027 1.73 (1.03–2.89) 0.037 GG 22 (18.64) 52 (18.57) 1.44 (0.76–2.76) 0.266 1.42 (0.74–2.74) 0.291 Additive 0.085 1.25 (0.92–1.70) 0.158 1.23 (0.90–1.69) 0.186 Dominant 89 (75.42) 181 (64.64) 0.036 1.68 (1.03–2.73) 0.037 1.64 (1.004–2.68) 0.048 Recessive 96 (81.36) 228 (81.43) 0.986 1.01 (0.58–1.75) 0.986 1.00 (0.57–1.74) 1.000 Combined (HWE = 0.164) CC 117 (29.77) 294 (36.30) 1.00 1.00 CG 197 (50.13) 372 (45.93) 1.33 (1.01–1.75) 0.042 1.33 (1.01–1.75) 0.045 GG 79 (20.10) 144 (17.78) 1.38 (0.97–1.95) 0.071 1.38 (0.97–1.95) 0.074 Additive 0.080 1.19 (1.01–1.41) 0.043 1.19 (1.004–1.41) 0.045 Dominant 276 (70.23) 516 (63.70) 0.025 1.34 (1.04–1.74) 0.025 1.34 (1.03–1.74) 0.028 Recessive 314 (79.90) 666 (82.22) 0.331 1.16 (0.86–1.58) 0.331 1.16 (0.86–1.58) 0.333 a 2 χ test for genotype distribution in neuroblastoma cases and cancer-free controls Adjusted for age and gender OR odds ratio, CI confidence interval The values were in bold if the 95% CI excluded 1, or P<0.05 No significant difference in CC, CG, and GG genotype CG/GG genotypes in children younger than 18 months distributions was found in the Guangdong subgroup, in- were associated with increased neuroblastoma risk (ad- dicating that the Lnc-LAMC2–1:1 rs2147578 C > G poly- justed OR = 1.70, 95% CI = 1.08–2.67, P = 0.022). Fe- morphism is not associated with neuroblastoma risk in males with the CG/GG genotypes were associated with the Guangdong study population. However, the increased neuroblastoma risk (adjusted OR = 2.08, 95% lnc-LAMC2–1:1 rs2147578 C > G polymorphism was as- CI = 1.37–3.18, P = 0.0007). In addition, Individuals with sociated with increased neuroblastoma risk in the Henan the CG/GG genotypes tended to be in an earlier clinical population (CG vs. CC: adjusted OR = 1.73, 95% CI = stage of neuroblastoma (adjusted OR = 1.46, 95% CI = 1.01– 1.03–2.89, P = 0.048; CG/GG vs. CC: adjusted OR = 1.64, 2.12, P = 0.046). Finally, no significant association between 95% CI = 1.004–2.68, P = 0.048). the lnc-LAMC2–1:1 rs2147578 C > G polymorphism and The combined analysis showed that the distribution of the site of tumor origin was found (Table 2). the CG genotype was significantly higher in the neuro- blastoma group (adjusted OR = 1.33, 95% CI = 1.01–1.75, Discussion P = 0.045), indicating that the lnc-LAMC2–1:1 rs2147578 In this study, we investigated the association between CG/GG genotype carriers had an increased risk of neuro- the lnc-LAMC2–1:1 rs2147578 C > G polymorphism and blastoma (CG/GG vs. CC: adjusted OR = 1.34, 95% CI = neuroblastoma susceptibility in Chinese Han popula- 1.03–1.74, P =0.028). tions. We found that the lnc-LAMC2–1:1 rs2147578 C > G polymorphism is associated with increased neuro- Stratification analysis of the lnc-LAMC2–1:1 rs2147578 C > blastoma susceptibility. Specifically, females and children G polymorphism and neuroblastoma risk younger than 18 months with specific genotypes in the Stratification analyses according to age, gender, site of lnc-LAMC2–1:1 rs2147578 C > G polymorphism are at origin, and clinical stage were further conducted. The an increased risk of neuroblastoma. Fortunately, Yang et al. BMC Cancer (2018) 18:948 Page 4 of 6 Table 2 Stratification analysis of the association between the lnc-LAMC2–1:1 rs2147578 C > G polymorphism and neuroblastoma susceptibility for combined subjects a a Variable rs2147578 (case/control) Crude OR P Adjusted OR P CC CG/GG (95% CI) (95% CI) Age, month ≤ 18 35/120 91/184 1.70 (1.08–2.67) 0.022 1.70 (1.08–2.67) 0.022 > 18 82/174 185/332 1.18 (0.86–1.63) 0.302 1.18 (0.86–1.62) 0.312 Gender Female 39/130 129/211 2.04 (1.34–3.10) 0.0009 2.08 (1.37–3.18) 0.0007 Male 78/164 147/305 1.01 (0.73–1.42) 0.938 1.00 (0.72–1.40) 0.981 Site of origin Adrenal gland 43/294 110/516 1.46 (1.00–2.13) 0.052 1.41 (0.96–2.07) 0.077 Retroperitoneal region 31/294 56/516 1.03 (0.65–1.63) 0.903 1.04 (0.66–1.66) 0.863 Mediastinum 32/294 77/516 1.37 (0.89–2.12) 0.157 1.39 (0.90–2.16) 0.138 Others 9/294 27/516 1.71 (0.79–3.68) 0.171 1.75 (0.81–3.78) 0.155 Clinical stage I + II + 4 s 46/294 116/516 1.44 (0.99–2.08) 0.055 1.46 (1.01–2.12) 0.046 III + IV 68/294 143/516 1.20 (0.87–1.65) 0.272 1.16 (0.84–1.61) 0.362 Adjusted for age and gender OR odds ratio; CI confidence interval The values were in bold if the 95% CI excluded 1, or P<0.05 individuals with the CG/GG variation tended to have the LAMC2 can interact with the epidermal growth factor re- earlier stages of neuroblastoma. ceptor (EGFR), and influence its downstream pathway [38]. Neuroblastoma accounts for approximately 15% of all Previous studies revealed that the EGF receptor is overex- childhood cancer mortality, and understanding the under- pressed in neuroblastoma tissues and cells, and anti-EGFR lying mechanisms of this disease would be of great value for agents are potential targeted therapies for neuroblastoma diagnosis and treatment [1, 2]. Genetic variants are critical [39–41]. The possible interaction between the lnc-LAMC2– in neuroblastoma tumorigenesis and disease progression. 1:1 rs2147578 polymorphism and the EGFR pathway may Missense mutations in PHOX2B, located on chromosome account for the increased risk of neuroblastoma of the G 4p, were the first germline mutations identified to be associ- allele. ated with neuroblastoma predisposition. Other genetic mu- Our results from Guangdong (Southern China) and tations, such as SNPs in the ALK and BARD1 genes and Henan (Northern China) provinces were inconsistent. In the copy number polymorphism of NBPF23, may also have a Henanprovincesubgroup, theCGgenotypedistribution role in neuroblastoma development [6–8]. was significantly higher in the neuroblastoma group, and LncRNAs are involved in many biological processes, with subjects with the GG and CG genotypes had a significantly LncRNA-MALAT1 and GAS5 being reported to mediate cell increased risk of neuroblastoma. In contrast, no association invasion, migration, and apoptosis in human neuroblastoma between the G allele and neuroblastoma was found in the [34, 35]. The lnc-LAMC2–1:1 polymorphism is located in Guangdong province subgroup. A possible explanation for the LAMC1 gene and close to the LAMC2 gene. Rs2147578 this inconsistency may be the relatively complex genetic is in the first exon of lnc-LAMC2–1:1, and the 26th intron background of the Guangdong Chinese Han population. of the LAMC1 gene near the LAMC2 gene [21]. Carriers Studies on Y-chromosome phylogeny suggest that people in with the G allele have a slightly increased expression of Southern China, including Guangdong province, are much lnc-LAMC2–1:1 through binding between rs2147578G and more polymorphic than populations in Northern China, in- miR-128-3p [21]. Previous evidence also suggests that the cluding Henan province [42–44]. However, the relatively lnc-LAMC2–1:1 rs2147578 C > G polymorphism may con- smallsamplesizeofour studymay introducebias. tribute to childhood ALL development [22]. Our results show that the lnc-LAMC2–1:1 rs2147578 C > G polymorph- Conclusion ism may also be involved in neuroblastoma tumorigenesis. The Lnc-LAMC2–1:1 rs2147578 C > G polymorphism is as- Abnormal expression of LAMC2 was found in several sociated with increased neuroblastoma susceptibility in Han types of cancer, and elevated expression of LAMC2 is associ- populations of Northern China. Female individuals and chil- ated with poor clinical outcome and relapse [36, 37]. dren younger than 18 months with such genetic variants are Yang et al. BMC Cancer (2018) 18:948 Page 5 of 6 at an increased risk for neuroblastoma. But with samples Received: 28 March 2018 Accepted: 21 September 2018 collected from only two provinces, we can’tmakeany solid conclusion. We might look into this question in the near fu- References ture when we collect more samples. 1. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003;3:203–16. 2. Kamijo T, Nakagawara A. Molecular and genetic bases of neuroblastoma. Int Additional file J Clin Oncol. 2012;17:190–5. 3. Bagatell R, Beck-Popovic M, London WB, Zhang Y, Pearson AD, Matthay KK, et Additional file 1: Table S1. Clinical characteristics of neuroblastoma al. Significance of MYCN amplification in international neuroblastoma staging cases and cancer-free controls. (DOCX 15 kb) system stage 1 and 2 neuroblastoma: a report from the international neuroblastoma risk group database. J Clin Oncol. 2009;27:365–70. 4. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, et Abbreviations al. The international neuroblastoma risk group (INRG) classification system: ALK: Anaplastic lymphoma kinase; ALL: Acute lymphoblastic leukemia; an INRG task force report. J Clin Oncol. 2009;27:289–97. CI: Confidence interval; EGFR: Epidermal growth factor receptor; 5. Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, et al. GWAS: Genome-wide association study; INSS: International Neuroblastoma The international neuroblastoma risk group (INRG) staging system: an INRG Staging System; LncRNA: Long non-coding RNAs; OR: Odds ratio; SNP: Single task force report. J Clin Oncol. 2009;27(2):298–303. nucleotide polymorphism 6. Trochet D, O'Brien LM, Gozal D, Trang H, Nordenskjold A, Laudier B, et al. PHOX2B genotype allows for prediction of tumor risk in congenital central Funding hypoventilation syndrome. Am J Hum Genet. 2005;76:421–6. This study was funded by the Pearl River S&T Nova Programme of 7. McConville C, Reid S, Baskcomb L, Douglas J, Rahman N. PHOX2B analysis in Guangzhou (No: 201710010086), the National Natural Science Foundation of non-syndromic neuroblastoma cases shows novel mutations and genotype- China (No: 81602199), the Guangzhou Science Technology and Innovation phenotype associations. Am J Med Genet A. 2006;140:1297–301. Commission (No: 201607010395), the Natural Science Foundation of 8. Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, et al. Guangdong Province, China (No: 2016A030313496), and National Natural Identification of ALK as a major familial neuroblastoma predisposition gene. Science Foundation of China (No: 81602199). The funding body has no role Nature. 2008;455:930–5. in the design of the study and collection, analysis, and interpretation of data 9. Caren H, Abel F, Kogner P, Martinsson T. High incidence of DNA mutations and in writing the manuscript. and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J. 2008;416:153–9. Availability of data and materials 10. George RE, Sanda T, Hanna M, Frohling S, Luther W, 2nd, Zhang J, et al. The datasets used during the current study are available from the Activating mutations in ALK provide a therapeutic target in neuroblastoma. corresponding author on reasonable request. Nature 2008;455:975–978. 11. Rando TA, Chang HY. Aging, rejuvenation, and epigenetic reprogramming: Authors’ contributions resetting the aging clock. Cell. 2012;148:46–57. TY, JH, YZ made substantial contributions to conception and design of this 12. Batista PJ, Chang HY. Long noncoding RNAs: cellular address codes in study. ZZ, JZ, TT, JP, CH, and JL make substantial contribution to the development and disease. Cell. 2013;152:1298–307. acquision of data, and interpretation of data. TY, JH, JY, and HX made 13. Prensner JR, Chinnaiyan AM. The emergence of lncRNAs in cancer biology. substantial contribution to statistical analysis and interpretation of data. TY, Cancer Discov. 2011;1:391–407. SL, YZ had been involved in drafting the manuscript and revising it critically 14. Mattick JS. Non-coding RNAs: the architects of eukaryotic complexity. EMBO for important intellectual content. YZ and JH were agreed to be accountable Rep. 2001;2:986–91. for all aspects of the work in ensuring that questions related to the accuracy 15. Jeon Y, Sarma K, Lee JT. New and Xisting regulatory mechanisms of X or integrity of any part of the work are appropriately investigated and chromosome inactivation. Curr Opin Genet Dev. 2012;22:62–71. resolved. TY, and ZZ contributed to the work equally. All authors had given 16. Wapinski O, Chang HY. Long noncoding RNAs and human disease. Trends final approval of the version to be published. Cell Mol Biol. 2011;21:354–61. 17. Pandey RR, Kanduri C. Transcriptional and posttranscriptional programming Ethics approval and consent to participate by long noncoding RNAs. Prog Mol Subcell Biol. 2011;51:1–27. This study was approved by the Institutional Review Board of 18. Liu Y, Pan S, Liu L, Zhai X, Liu J, Wen J, et al. A genetic variant in long non- Guangzhou Women and Children’s Medical Center (Guangzhou, China). coding RNA HULC contributes to risk of HBV-related hepatocellular Written informed consent was obtained from the parents of the carcinoma in a Chinese population. PLoS One. 2012;7:e35145. participants or their legal guardians for the use of their children’s 19. Maris JM, Mosse YP, Bradfield JP, Hou C, Monni S, Scott RH, et al. medical data and biological samples. All patient records/data were Chromosome 6p22 locus associated with clinically aggressive anonymized and de-identified prior to analysis. neuroblastoma. N Engl J Med. 2008;358:2585–93. 20. Diskin SJ, Capasso M, Schnepp RW, Cole KA, Attiyeh EF, Hou C, et al. Consent for publication Common variation at 6q16 within HACE1 and LIN28B influences Not applicable. susceptibility to neuroblastoma. Nat Genet. 2012;44:1126–30. 21. Gong J, Tian J, Lou J, Ke J, Li L, Li J, et al. A functional polymorphism in lnc- LAMC2-1:1 confers risk of colorectal cancer by affecting miRNA binding. Competing interests Carcinogenesis. 2016;37:443–51. The authors declare that they have no competing interests. 22. Hashemi M, Bahari G, Naderi M, Sadeghi-Bojd S, Taheri M. Association of lnc- LAMC2-1:1 rs2147578 and CASC8 rs10505477 polymorphisms with risk of Publisher’sNote childhood acute lymphoblastic leukemia. Asian Pac J Cancer Prev. 2016;17:4985–9. Springer Nature remains neutral with regard to jurisdictional claims in 23. He J, Zou Y, Liu X, Zhu J, Zhang J, Zhang R, et al. Association of common genetic published maps and institutional affiliations. variants in pre-microRNAs and neuroblastoma susceptibility: a two-center case- control study in Chinese children. Mol Ther Nucleic Acids. 2018;11:1–8. Author details 24. Zhang Z, Chang Y, Jia W, Zhang J, Zhang R, Zhu J, et al. LINC00673 Department of Pediatric Surgery, Guangzhou Women and Children’s rs11655237 C>T confers neuroblastoma susceptibility in Chinese population. Medical Center, Guangzhou Medical University, 9 Jinsui Road, Guangzhou Biosci Rep. 2018;38:BSR20171667. 510623, Guangdong, China. Department of Pediatric Surgery, The First 25. Zhang J, Lin H, Wang J, He J, Zhang D, Qin P, et al. LMO1 polymorphisms Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, reduce neuroblastoma risk in Chinese children: a two-center case-control China. study. Oncotarget. 2017;8:65620–6. Yang et al. BMC Cancer (2018) 18:948 Page 6 of 6 26. Zhang J, Zhuo ZJ, Wang J, He J, Yang L, Zhang D, et al. CASC15 gene polymorphisms reduce neuroblastoma risk in Chinese children. Oncotarget. 2017;8:91343–9. 27. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, et al. The international neuroblastoma pathology classification (the Shimada system). Cancer. 1999;86:364–72. 28. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466–77. 29. Gong J, Tian J, Lou J, Wang X, Ke J, Li J, et al. A polymorphic MYC response element in KBTBD11 influences colorectal cancer risk, especially in interaction with a MYC regulated SNP rs6983267. Ann Oncol. 2018;29:632–9. 30. Li J, Zou L, Zhou Y, Li L, Zhu Y, Yang Y, et al. A low-frequency variant in SMAD7 modulates TGF-beta signaling and confers risk for colorectal cancer in Chinese population. Mol Carcinog. 2017;56:1798–807. 31. Lou J, Gong J, Ke J, Tian J, Zhang Y, Li J, et al. A functional polymorphism located at transcription factor binding sites, rs6695837 near LAMC1 gene, confers risk of colorectal cancer in Chinese populations. Carcinogenesis. 2017;38:177–83. 32. He J, Qiu LX, Wang MY, Hua RX, Zhang RX, Yu HP, et al. Polymorphisms in the XPG gene and risk of gastric cancer in Chinese populations. Hum Genet. 2012;131:1235–44. 33. He J, Wang F, Zhu J, Zhang R, Yang T, Zou Y, et al. Association of potentially functional variants in the XPG gene with neuroblastoma risk in a Chinese population. J Cell Mol Med. 2016;20:1481–90. 34. Bi S, Wang C, Li Y, Zhang W, Zhang J, Lv Z, et al. LncRNA-MALAT1-mediated Axl promotes cell invasion and migration in human neuroblastoma. Tumour Biol. 2017;39:1010428317699796. 35. Mazar J, Rosado A, Shelley J, Marchica J, Westmoreland TJ. The long non- coding RNA GAS5 differentially regulates cell cycle arrest and apoptosis through activation of BRCA1 and p53 in human neuroblastoma. Oncotarget. 2017;8:6589–607. 36. Takahashi S, Hasebe T, Oda T, Sasaki S, Kinoshita T, Konishi M, et al. Cytoplasmic expression of laminin gamma2 chain correlates with postoperative hepatic metastasis and poor prognosis in patients with pancreatic ductal adenocarcinoma. Cancer. 2002;94:1894–901. 37. Yamamoto H, Itoh F, Iku S, Hosokawa M, Imai K. Expression of the gamma(2) chain of laminin-5 at the invasive front is associated with recurrence and poor prognosis in human esophageal squamous cell carcinoma. Clin Cancer Res. 2001;7:896–900. 38. Garg M, Kanojia D, Okamoto R, Jain S, Madan V, Chien W, et al. Laminin-5 gamma-2 (LAMC2) is highly expressed in anaplastic thyroid carcinoma and is associated with tumor progression, migration, and invasion by modulating signaling of EGFR. J Clin Endocrinol Metab. 2014;99:E62–72. 39. Evangelopoulos ME,WeisJ,Kruttgen A. Signalling pathways leading to neuroblastoma differentiation after serum withdrawal: HDL blocks neuroblastoma differentiation by inhibition of EGFR. Oncogene. 2005;24:3309–18. 40. Michaelis M, Bliss J, Arnold SC, Hinsch N, Rothweiler F, Deubzer HE, et al. Cisplatin-resistant neuroblastoma cells express enhanced levels of epidermal growth factor receptor (EGFR) and are sensitive to treatment with EGFR- specific toxins. Clin Cancer Res. 2008;14:6531–7. 41. Zheng C, Shen R, Li K, Zheng N, Zong Y, Ye D, et al. Epidermal growth factor receptor is overexpressed in neuroblastoma tissues and cells. Acta Biochim Biophys Sin. 2016;48:762–7. 42. Deng W, Shi B, He X, Zhang Z, Xu J, Li B, et al. Evolution and migration history of the Chinese population inferred from Chinese Y-chromosome evidence. J Hum Genet. 2004;49:339–48. 43. Shen P, Wang F, Underhill PA, Franco C, Yang WH, Roxas A, et al. Population genetic implications from sequence variation in four Y chromosome genes. Proc Natl Acad Sci U S A. 2000;97:7354–9. 44. Underhill PA, Shen P, Lin AA, Jin L, Passarino G, Yang WH, et al. Y chromosome sequence variation and the history of human populations. Nat Genet. 2000;26:358–61. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png BMC Cancer Springer Journals

The rs2147578C > G polymorphism in the Inc-LAMC2–1:1 gene is associated with increased neuroblastoma risk in the Henan children

Loading next page...
 
/lp/springer-journals/the-rs2147578c-g-polymorphism-in-the-inc-lamc2-1-1-gene-is-associated-ZppuwCcYaA
Publisher
Springer Journals
Copyright
Copyright © 2018 by The Author(s).
Subject
Biomedicine; Cancer Research; Oncology; Surgical Oncology; Health Promotion and Disease Prevention; Biomedicine, general; Medicine/Public Health, general
eISSN
1471-2407
D.O.I.
10.1186/s12885-018-4847-y
Publisher site
See Article on Publisher Site

Abstract

Background: The rs2147578 C > G polymorphism in the long non-coding RNA gene Lnc-LAMC2–1:1 is associated with increased susceptibility to a few types of cancers. However, its role in neuroblastoma has not been evaluated yet. Methods: We investigated the association between the lnc-LAMC2–1:1 rs2147578 C > G polymorphism and neuroblastoma susceptibility in Chinese Han populations. A total of 393 neuroblastoma cases and 812 healthy individuals from the Henan and Guangdong provinces were enrolled and subjected to genotyping. Odds ratio (OR) and 95% confidence interval (CI) were used to determine the strength of the association of interest. Results: Combined analysis revealed that the lnc-LAMC2–1:1 rs2147578 C > G polymorphism was associated with increased neuroblastoma susceptibility (CG vs. CC: adjusted OR = 1.33, 95% CI = 1.01–1.75, P = 0.045; CG/GG vs. CC: adjusted OR = 1.34, 95% CI = 1.03–1.74, P = 0.028). In stratification analysis, children under 18 months with rs2147578 CG/GG genotypes had an increased neuroblastoma risk (adjusted OR = 1.70, 95% CI = 1.08–2.67, P = 0.022). Females with rs2147578 CG/GG genotypes also had increased neuroblastoma susceptibility (adjusted OR = 2.08, 95% CI = 1.37– 3.18, P = 0.0007). In addition, children with lnc-LAMC2–1:1 rs2147578 CG/GG genotypes were prone to develop earlier stages of neuroblastoma (adjusted OR = 1.46, 95% CI = 1.01–2.12, P =0.046). Conclusions: The Lnc-LAMC2–1:1 rs2147578 C > G polymorphism may contribute to increased neuroblastoma susceptibility in children of Henan province. Keywords: rs2147578, Neuroblastoma, Long non-coding RNA, Polymorphism Background stage, N-myc status, DNA ploidy, and structural chromo- Neuroblastoma is the most common malignant extracranial somal aberrations [3–5]. solid tumor in children, accounting for 7–10% of all tumors Genetic factors are critically important in neuroblast- [1, 2]. Neuroblastoma originates from neural crest precur- oma tumorigenesis. Approximately 1% of the patients sor cells of the sympathetic nervous system and is mainly have a family history of neuroblastoma, and are carriers of located in the adrenal medulla, paraspinal ganglia, and certain genetic mutations. For instance, anaplastic lymph- sympathetic trunk [3–5]. The outcome of neuroblastoma is oma kinase (ALK)and PHOX2B gene variants are among affected by several factors such as age of onset, pathological the predisposing factors to familial neuroblastoma [6–8]. subtype, International Neuroblastoma Staging System (INSS) Evidence of genome-wide association studies (GWASs) of sporadic cases also suggests that genetic factors may be in- * Correspondence: hejing198374@gmail.com; hejing@gwcmc.org; volved in the pathogenesis of neuroblastoma [9, 10]. These 378319696@qq.com; monknut@126.com 1 studies indicate an important role of genetic characteris- Department of Pediatric Surgery, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, 9 Jinsui Road, Guangzhou tics in the tumorigenesis of this disease. 510623, Guangdong, China Full list of author information is available at the end of the article © The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. Yang et al. BMC Cancer (2018) 18:948 Page 2 of 6 Long non-coding RNAs (lncRNAs) are mRNA-like their legal guardians for the use of their children’smedical molecules whose genes belong to the non-protein coding data and biological samples. genome. LncRNAs are involved in many biological pro- cesses such as gene imprinting, epigenetic regulation, SNP selection and genotyping translational regulation, splicing, and aging [11–15]. The Lnc-LAMC2–1:1 rs2147578 C > G polymorphism LncRNAs are also involved in apoptosis and cell differ- was genotyped using the TaqMan real-time PCR system entiation, which are critical in tumorigenesis [16, 17]. on a 7900 Sequence Detection System (Applied Biosys- LncRNAs such as HULC, PCAT-1, HOTAIR, ANRIL, tems, Foster City, CA), as described previously [29–31]. and H19 are found to play important roles in cancer de- Briefly, high-quality DNA samples were genotyped using velopment [17]. Single nucleotide polymorphism (SNP) Taqman real-time PCR method on a 7900 HT sequence at HULC is associated with decreased hepatocellular car- detector system. The call rate for the SNPs was 99%, cinoma risk [18]. GWAS show that neuroblastoma pa- which met the pre-set criterion. For quality control, tients with the G allele of SNP rs6939340, which is eight duplicate positive and eight negative controls with- located in the lncRNA LOC729177 gene, have a high out DNA were used in each 384-well plate [32, 33]. Add- risk of metastasis and poor outcome [19, 20]. These itionally, 10% samples were randomly selected and studies indicate that evaluation of lncRNA gene poly- repeated, and the reproducibility was 100% concordant. morphism would be of great value in the risk assessment of neuroblastoma. Statistical analysis The rs2147578 C > G polymorphism in the lncRNA All statistical tests were two-sided, with a significance gene Lnc-LAMC2–1:1 is associated with susceptibility to level of P < 0.05. All statistical analyses were performed several types of cancer, and functional polymorphism in using SAS software (Version 9.4; SAS Institute, Cary, lnc-LAMC2–1:1 may confer a high risk of colorectal NC, USA). Two-sided χ tests were used to analyze cancer through affecting miRNA binding [21]. Moreover, demographic data and genotype frequencies. The the lnc-LAMC2–1:1 rs2147578 polymorphism is also Hardy-Weinberg equilibrium was assessed using the considered a possible risk factor for acute lymphoblastic goodness-of-χ test. Odds ratios (OR) and 95% confi- leukemia (ALL) in children [22]. However, few studies dence intervals (CIs) were calculated using the Woolf have focused on this polymorphism in neuroblastoma. approximation method to evaluate association between Here we hypothesized that the lnc-LAMC2–1:1 rs214757 the lnc-LAMC2–1:1 rs2147578 C > G polymorphism and 8 C > G polymorphism may contribute to neuroblastoma neuroblastoma susceptibility. Crude and age- and susceptibility, and we tested our hypothesis via a gender-adjusted OR were evaluated using the uncondi- case-control study. tional logistic regression method. Results Materials and methods Demographic characteristics of the study population Study subjects A total of 275 cases of neuroblastoma and 531 health The subjects enrolled were described in previous studies controls in Guangdong province and 118 neuroblastoma [23, 24]. Briefly, 393 neuroblastoma patients and 812 cases and 281 health controls in Henan province were cancer-free controls were enrolled from two different prov- evaluated (Additional File 1 Table S1). Age and gender inces of China: 275 neuroblastoma patients and 531 controls distributions were similar between cases and controls in from the Guangzhou Women and Children’s Medical Cen- both Guangdong and Henan province subgroups (P > ter in Southern China, and 118 neuroblastoma patients and 0.05). Distribution of clinical stages and sites of tumor 281 controls from the Henan province in Northern China origin are also listed in Additional file 1 Table S1. [25, 26]. Diagnosis and clinical stages of neuroblastoma were assigned according to the Shimada system and the inter- Lnc-LAMC2–1:1 rs2147578 C > G polymorphism and national criteria for neuroblastoma staging system [27, 28]. susceptibility to neuroblastoma Healthy controls had no history of malignancies and were Genotype and allele frequencies of the lnc-LAMC2–1:1 matched to the neuroblastoma cases in terms of age rs2147578 C > G polymorphism and associations with (±5 years), gender, ethnicity, and geographical region. Both neuroblastoma risk are summarized in Table 1. In both cases and controls were unrelated Chinese Han individuals combined and subgroup analyses, the genotype distribu- living in the Guangdong and Henan provinces of China. tion of the lnc-LAMC2–1:1 rs2147578 C > G polymorph- This study was approved by the Institutional Review ism in the controls and cases were consistent with Board of Guangzhou Women and Children’sMedical Hardy-Weinberg equilibrium (P = 0.164 for combined Center (Guangzhou, China), and written informed con- subjects, P = 0.279 for Guangdong province, and sent was obtained from the parents of the participants or P = 0.386 for Henan province). Yang et al. BMC Cancer (2018) 18:948 Page 3 of 6 Table 1 Genotype distribution of the lnc-LAMC2–1:1 rs2147578 C > G polymorphism and neuroblastoma susceptibility a b Genotype Case Control P Crude OR P Adjusted OR P (95% CI) (95% CI) Guangdong province (HWE = 0.279) CC 88 (32.00) 195 (36.79) 1.00 1.00 CG 130 (47.27) 243 (45.85) 1.19 (0.85–1.65) 0.312 1.18 (0.85–1.64) 0.332 GG 57 (20.73) 92 (17.36) 1.37 (0.91–2.08) 0.135 1.38 (0.91–2.10) 0.127 Additive 0.305 1.17 (0.96–1.44) 0.124 1.18 (0.96–1.44) 0.120 Dominant 187 (68.00) 335 (63.21) 0.177 1.24 (0.91–1.68) 0.177 1.23 (0.91–1.68) 0.183 Recessive 218 (79.27) 438 (82.64) 0.243 1.25 (0.86–1.80) 0.244 1.26 (0.87–1.82) 0.223 Henan province (HWE = 0.386) CC 29 (24.58) 99 (35.36) 1.00 1.00 CG 67 (56.78) 129 (46.07) 1.77 (1.07–2.95) 0.027 1.73 (1.03–2.89) 0.037 GG 22 (18.64) 52 (18.57) 1.44 (0.76–2.76) 0.266 1.42 (0.74–2.74) 0.291 Additive 0.085 1.25 (0.92–1.70) 0.158 1.23 (0.90–1.69) 0.186 Dominant 89 (75.42) 181 (64.64) 0.036 1.68 (1.03–2.73) 0.037 1.64 (1.004–2.68) 0.048 Recessive 96 (81.36) 228 (81.43) 0.986 1.01 (0.58–1.75) 0.986 1.00 (0.57–1.74) 1.000 Combined (HWE = 0.164) CC 117 (29.77) 294 (36.30) 1.00 1.00 CG 197 (50.13) 372 (45.93) 1.33 (1.01–1.75) 0.042 1.33 (1.01–1.75) 0.045 GG 79 (20.10) 144 (17.78) 1.38 (0.97–1.95) 0.071 1.38 (0.97–1.95) 0.074 Additive 0.080 1.19 (1.01–1.41) 0.043 1.19 (1.004–1.41) 0.045 Dominant 276 (70.23) 516 (63.70) 0.025 1.34 (1.04–1.74) 0.025 1.34 (1.03–1.74) 0.028 Recessive 314 (79.90) 666 (82.22) 0.331 1.16 (0.86–1.58) 0.331 1.16 (0.86–1.58) 0.333 a 2 χ test for genotype distribution in neuroblastoma cases and cancer-free controls Adjusted for age and gender OR odds ratio, CI confidence interval The values were in bold if the 95% CI excluded 1, or P<0.05 No significant difference in CC, CG, and GG genotype CG/GG genotypes in children younger than 18 months distributions was found in the Guangdong subgroup, in- were associated with increased neuroblastoma risk (ad- dicating that the Lnc-LAMC2–1:1 rs2147578 C > G poly- justed OR = 1.70, 95% CI = 1.08–2.67, P = 0.022). Fe- morphism is not associated with neuroblastoma risk in males with the CG/GG genotypes were associated with the Guangdong study population. However, the increased neuroblastoma risk (adjusted OR = 2.08, 95% lnc-LAMC2–1:1 rs2147578 C > G polymorphism was as- CI = 1.37–3.18, P = 0.0007). In addition, Individuals with sociated with increased neuroblastoma risk in the Henan the CG/GG genotypes tended to be in an earlier clinical population (CG vs. CC: adjusted OR = 1.73, 95% CI = stage of neuroblastoma (adjusted OR = 1.46, 95% CI = 1.01– 1.03–2.89, P = 0.048; CG/GG vs. CC: adjusted OR = 1.64, 2.12, P = 0.046). Finally, no significant association between 95% CI = 1.004–2.68, P = 0.048). the lnc-LAMC2–1:1 rs2147578 C > G polymorphism and The combined analysis showed that the distribution of the site of tumor origin was found (Table 2). the CG genotype was significantly higher in the neuro- blastoma group (adjusted OR = 1.33, 95% CI = 1.01–1.75, Discussion P = 0.045), indicating that the lnc-LAMC2–1:1 rs2147578 In this study, we investigated the association between CG/GG genotype carriers had an increased risk of neuro- the lnc-LAMC2–1:1 rs2147578 C > G polymorphism and blastoma (CG/GG vs. CC: adjusted OR = 1.34, 95% CI = neuroblastoma susceptibility in Chinese Han popula- 1.03–1.74, P =0.028). tions. We found that the lnc-LAMC2–1:1 rs2147578 C > G polymorphism is associated with increased neuro- Stratification analysis of the lnc-LAMC2–1:1 rs2147578 C > blastoma susceptibility. Specifically, females and children G polymorphism and neuroblastoma risk younger than 18 months with specific genotypes in the Stratification analyses according to age, gender, site of lnc-LAMC2–1:1 rs2147578 C > G polymorphism are at origin, and clinical stage were further conducted. The an increased risk of neuroblastoma. Fortunately, Yang et al. BMC Cancer (2018) 18:948 Page 4 of 6 Table 2 Stratification analysis of the association between the lnc-LAMC2–1:1 rs2147578 C > G polymorphism and neuroblastoma susceptibility for combined subjects a a Variable rs2147578 (case/control) Crude OR P Adjusted OR P CC CG/GG (95% CI) (95% CI) Age, month ≤ 18 35/120 91/184 1.70 (1.08–2.67) 0.022 1.70 (1.08–2.67) 0.022 > 18 82/174 185/332 1.18 (0.86–1.63) 0.302 1.18 (0.86–1.62) 0.312 Gender Female 39/130 129/211 2.04 (1.34–3.10) 0.0009 2.08 (1.37–3.18) 0.0007 Male 78/164 147/305 1.01 (0.73–1.42) 0.938 1.00 (0.72–1.40) 0.981 Site of origin Adrenal gland 43/294 110/516 1.46 (1.00–2.13) 0.052 1.41 (0.96–2.07) 0.077 Retroperitoneal region 31/294 56/516 1.03 (0.65–1.63) 0.903 1.04 (0.66–1.66) 0.863 Mediastinum 32/294 77/516 1.37 (0.89–2.12) 0.157 1.39 (0.90–2.16) 0.138 Others 9/294 27/516 1.71 (0.79–3.68) 0.171 1.75 (0.81–3.78) 0.155 Clinical stage I + II + 4 s 46/294 116/516 1.44 (0.99–2.08) 0.055 1.46 (1.01–2.12) 0.046 III + IV 68/294 143/516 1.20 (0.87–1.65) 0.272 1.16 (0.84–1.61) 0.362 Adjusted for age and gender OR odds ratio; CI confidence interval The values were in bold if the 95% CI excluded 1, or P<0.05 individuals with the CG/GG variation tended to have the LAMC2 can interact with the epidermal growth factor re- earlier stages of neuroblastoma. ceptor (EGFR), and influence its downstream pathway [38]. Neuroblastoma accounts for approximately 15% of all Previous studies revealed that the EGF receptor is overex- childhood cancer mortality, and understanding the under- pressed in neuroblastoma tissues and cells, and anti-EGFR lying mechanisms of this disease would be of great value for agents are potential targeted therapies for neuroblastoma diagnosis and treatment [1, 2]. Genetic variants are critical [39–41]. The possible interaction between the lnc-LAMC2– in neuroblastoma tumorigenesis and disease progression. 1:1 rs2147578 polymorphism and the EGFR pathway may Missense mutations in PHOX2B, located on chromosome account for the increased risk of neuroblastoma of the G 4p, were the first germline mutations identified to be associ- allele. ated with neuroblastoma predisposition. Other genetic mu- Our results from Guangdong (Southern China) and tations, such as SNPs in the ALK and BARD1 genes and Henan (Northern China) provinces were inconsistent. In the copy number polymorphism of NBPF23, may also have a Henanprovincesubgroup, theCGgenotypedistribution role in neuroblastoma development [6–8]. was significantly higher in the neuroblastoma group, and LncRNAs are involved in many biological processes, with subjects with the GG and CG genotypes had a significantly LncRNA-MALAT1 and GAS5 being reported to mediate cell increased risk of neuroblastoma. In contrast, no association invasion, migration, and apoptosis in human neuroblastoma between the G allele and neuroblastoma was found in the [34, 35]. The lnc-LAMC2–1:1 polymorphism is located in Guangdong province subgroup. A possible explanation for the LAMC1 gene and close to the LAMC2 gene. Rs2147578 this inconsistency may be the relatively complex genetic is in the first exon of lnc-LAMC2–1:1, and the 26th intron background of the Guangdong Chinese Han population. of the LAMC1 gene near the LAMC2 gene [21]. Carriers Studies on Y-chromosome phylogeny suggest that people in with the G allele have a slightly increased expression of Southern China, including Guangdong province, are much lnc-LAMC2–1:1 through binding between rs2147578G and more polymorphic than populations in Northern China, in- miR-128-3p [21]. Previous evidence also suggests that the cluding Henan province [42–44]. However, the relatively lnc-LAMC2–1:1 rs2147578 C > G polymorphism may con- smallsamplesizeofour studymay introducebias. tribute to childhood ALL development [22]. Our results show that the lnc-LAMC2–1:1 rs2147578 C > G polymorph- Conclusion ism may also be involved in neuroblastoma tumorigenesis. The Lnc-LAMC2–1:1 rs2147578 C > G polymorphism is as- Abnormal expression of LAMC2 was found in several sociated with increased neuroblastoma susceptibility in Han types of cancer, and elevated expression of LAMC2 is associ- populations of Northern China. Female individuals and chil- ated with poor clinical outcome and relapse [36, 37]. dren younger than 18 months with such genetic variants are Yang et al. BMC Cancer (2018) 18:948 Page 5 of 6 at an increased risk for neuroblastoma. But with samples Received: 28 March 2018 Accepted: 21 September 2018 collected from only two provinces, we can’tmakeany solid conclusion. We might look into this question in the near fu- References ture when we collect more samples. 1. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003;3:203–16. 2. Kamijo T, Nakagawara A. Molecular and genetic bases of neuroblastoma. Int Additional file J Clin Oncol. 2012;17:190–5. 3. Bagatell R, Beck-Popovic M, London WB, Zhang Y, Pearson AD, Matthay KK, et Additional file 1: Table S1. Clinical characteristics of neuroblastoma al. Significance of MYCN amplification in international neuroblastoma staging cases and cancer-free controls. (DOCX 15 kb) system stage 1 and 2 neuroblastoma: a report from the international neuroblastoma risk group database. J Clin Oncol. 2009;27:365–70. 4. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, et Abbreviations al. The international neuroblastoma risk group (INRG) classification system: ALK: Anaplastic lymphoma kinase; ALL: Acute lymphoblastic leukemia; an INRG task force report. J Clin Oncol. 2009;27:289–97. CI: Confidence interval; EGFR: Epidermal growth factor receptor; 5. Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, et al. GWAS: Genome-wide association study; INSS: International Neuroblastoma The international neuroblastoma risk group (INRG) staging system: an INRG Staging System; LncRNA: Long non-coding RNAs; OR: Odds ratio; SNP: Single task force report. J Clin Oncol. 2009;27(2):298–303. nucleotide polymorphism 6. Trochet D, O'Brien LM, Gozal D, Trang H, Nordenskjold A, Laudier B, et al. PHOX2B genotype allows for prediction of tumor risk in congenital central Funding hypoventilation syndrome. Am J Hum Genet. 2005;76:421–6. This study was funded by the Pearl River S&T Nova Programme of 7. McConville C, Reid S, Baskcomb L, Douglas J, Rahman N. PHOX2B analysis in Guangzhou (No: 201710010086), the National Natural Science Foundation of non-syndromic neuroblastoma cases shows novel mutations and genotype- China (No: 81602199), the Guangzhou Science Technology and Innovation phenotype associations. Am J Med Genet A. 2006;140:1297–301. Commission (No: 201607010395), the Natural Science Foundation of 8. Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, et al. Guangdong Province, China (No: 2016A030313496), and National Natural Identification of ALK as a major familial neuroblastoma predisposition gene. Science Foundation of China (No: 81602199). The funding body has no role Nature. 2008;455:930–5. in the design of the study and collection, analysis, and interpretation of data 9. Caren H, Abel F, Kogner P, Martinsson T. High incidence of DNA mutations and in writing the manuscript. and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J. 2008;416:153–9. Availability of data and materials 10. George RE, Sanda T, Hanna M, Frohling S, Luther W, 2nd, Zhang J, et al. The datasets used during the current study are available from the Activating mutations in ALK provide a therapeutic target in neuroblastoma. corresponding author on reasonable request. Nature 2008;455:975–978. 11. Rando TA, Chang HY. Aging, rejuvenation, and epigenetic reprogramming: Authors’ contributions resetting the aging clock. Cell. 2012;148:46–57. TY, JH, YZ made substantial contributions to conception and design of this 12. Batista PJ, Chang HY. Long noncoding RNAs: cellular address codes in study. ZZ, JZ, TT, JP, CH, and JL make substantial contribution to the development and disease. Cell. 2013;152:1298–307. acquision of data, and interpretation of data. TY, JH, JY, and HX made 13. Prensner JR, Chinnaiyan AM. The emergence of lncRNAs in cancer biology. substantial contribution to statistical analysis and interpretation of data. TY, Cancer Discov. 2011;1:391–407. SL, YZ had been involved in drafting the manuscript and revising it critically 14. Mattick JS. Non-coding RNAs: the architects of eukaryotic complexity. EMBO for important intellectual content. YZ and JH were agreed to be accountable Rep. 2001;2:986–91. for all aspects of the work in ensuring that questions related to the accuracy 15. Jeon Y, Sarma K, Lee JT. New and Xisting regulatory mechanisms of X or integrity of any part of the work are appropriately investigated and chromosome inactivation. Curr Opin Genet Dev. 2012;22:62–71. resolved. TY, and ZZ contributed to the work equally. All authors had given 16. Wapinski O, Chang HY. Long noncoding RNAs and human disease. Trends final approval of the version to be published. Cell Mol Biol. 2011;21:354–61. 17. Pandey RR, Kanduri C. Transcriptional and posttranscriptional programming Ethics approval and consent to participate by long noncoding RNAs. Prog Mol Subcell Biol. 2011;51:1–27. This study was approved by the Institutional Review Board of 18. Liu Y, Pan S, Liu L, Zhai X, Liu J, Wen J, et al. A genetic variant in long non- Guangzhou Women and Children’s Medical Center (Guangzhou, China). coding RNA HULC contributes to risk of HBV-related hepatocellular Written informed consent was obtained from the parents of the carcinoma in a Chinese population. PLoS One. 2012;7:e35145. participants or their legal guardians for the use of their children’s 19. Maris JM, Mosse YP, Bradfield JP, Hou C, Monni S, Scott RH, et al. medical data and biological samples. All patient records/data were Chromosome 6p22 locus associated with clinically aggressive anonymized and de-identified prior to analysis. neuroblastoma. N Engl J Med. 2008;358:2585–93. 20. Diskin SJ, Capasso M, Schnepp RW, Cole KA, Attiyeh EF, Hou C, et al. Consent for publication Common variation at 6q16 within HACE1 and LIN28B influences Not applicable. susceptibility to neuroblastoma. Nat Genet. 2012;44:1126–30. 21. Gong J, Tian J, Lou J, Ke J, Li L, Li J, et al. A functional polymorphism in lnc- LAMC2-1:1 confers risk of colorectal cancer by affecting miRNA binding. Competing interests Carcinogenesis. 2016;37:443–51. The authors declare that they have no competing interests. 22. Hashemi M, Bahari G, Naderi M, Sadeghi-Bojd S, Taheri M. Association of lnc- LAMC2-1:1 rs2147578 and CASC8 rs10505477 polymorphisms with risk of Publisher’sNote childhood acute lymphoblastic leukemia. Asian Pac J Cancer Prev. 2016;17:4985–9. Springer Nature remains neutral with regard to jurisdictional claims in 23. He J, Zou Y, Liu X, Zhu J, Zhang J, Zhang R, et al. Association of common genetic published maps and institutional affiliations. variants in pre-microRNAs and neuroblastoma susceptibility: a two-center case- control study in Chinese children. Mol Ther Nucleic Acids. 2018;11:1–8. Author details 24. Zhang Z, Chang Y, Jia W, Zhang J, Zhang R, Zhu J, et al. LINC00673 Department of Pediatric Surgery, Guangzhou Women and Children’s rs11655237 C>T confers neuroblastoma susceptibility in Chinese population. Medical Center, Guangzhou Medical University, 9 Jinsui Road, Guangzhou Biosci Rep. 2018;38:BSR20171667. 510623, Guangdong, China. Department of Pediatric Surgery, The First 25. Zhang J, Lin H, Wang J, He J, Zhang D, Qin P, et al. LMO1 polymorphisms Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, reduce neuroblastoma risk in Chinese children: a two-center case-control China. study. Oncotarget. 2017;8:65620–6. Yang et al. BMC Cancer (2018) 18:948 Page 6 of 6 26. Zhang J, Zhuo ZJ, Wang J, He J, Yang L, Zhang D, et al. CASC15 gene polymorphisms reduce neuroblastoma risk in Chinese children. Oncotarget. 2017;8:91343–9. 27. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, et al. The international neuroblastoma pathology classification (the Shimada system). Cancer. 1999;86:364–72. 28. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466–77. 29. Gong J, Tian J, Lou J, Wang X, Ke J, Li J, et al. A polymorphic MYC response element in KBTBD11 influences colorectal cancer risk, especially in interaction with a MYC regulated SNP rs6983267. Ann Oncol. 2018;29:632–9. 30. Li J, Zou L, Zhou Y, Li L, Zhu Y, Yang Y, et al. A low-frequency variant in SMAD7 modulates TGF-beta signaling and confers risk for colorectal cancer in Chinese population. Mol Carcinog. 2017;56:1798–807. 31. Lou J, Gong J, Ke J, Tian J, Zhang Y, Li J, et al. A functional polymorphism located at transcription factor binding sites, rs6695837 near LAMC1 gene, confers risk of colorectal cancer in Chinese populations. Carcinogenesis. 2017;38:177–83. 32. He J, Qiu LX, Wang MY, Hua RX, Zhang RX, Yu HP, et al. Polymorphisms in the XPG gene and risk of gastric cancer in Chinese populations. Hum Genet. 2012;131:1235–44. 33. He J, Wang F, Zhu J, Zhang R, Yang T, Zou Y, et al. Association of potentially functional variants in the XPG gene with neuroblastoma risk in a Chinese population. J Cell Mol Med. 2016;20:1481–90. 34. Bi S, Wang C, Li Y, Zhang W, Zhang J, Lv Z, et al. LncRNA-MALAT1-mediated Axl promotes cell invasion and migration in human neuroblastoma. Tumour Biol. 2017;39:1010428317699796. 35. Mazar J, Rosado A, Shelley J, Marchica J, Westmoreland TJ. The long non- coding RNA GAS5 differentially regulates cell cycle arrest and apoptosis through activation of BRCA1 and p53 in human neuroblastoma. Oncotarget. 2017;8:6589–607. 36. Takahashi S, Hasebe T, Oda T, Sasaki S, Kinoshita T, Konishi M, et al. Cytoplasmic expression of laminin gamma2 chain correlates with postoperative hepatic metastasis and poor prognosis in patients with pancreatic ductal adenocarcinoma. Cancer. 2002;94:1894–901. 37. Yamamoto H, Itoh F, Iku S, Hosokawa M, Imai K. Expression of the gamma(2) chain of laminin-5 at the invasive front is associated with recurrence and poor prognosis in human esophageal squamous cell carcinoma. Clin Cancer Res. 2001;7:896–900. 38. Garg M, Kanojia D, Okamoto R, Jain S, Madan V, Chien W, et al. Laminin-5 gamma-2 (LAMC2) is highly expressed in anaplastic thyroid carcinoma and is associated with tumor progression, migration, and invasion by modulating signaling of EGFR. J Clin Endocrinol Metab. 2014;99:E62–72. 39. Evangelopoulos ME,WeisJ,Kruttgen A. Signalling pathways leading to neuroblastoma differentiation after serum withdrawal: HDL blocks neuroblastoma differentiation by inhibition of EGFR. Oncogene. 2005;24:3309–18. 40. Michaelis M, Bliss J, Arnold SC, Hinsch N, Rothweiler F, Deubzer HE, et al. Cisplatin-resistant neuroblastoma cells express enhanced levels of epidermal growth factor receptor (EGFR) and are sensitive to treatment with EGFR- specific toxins. Clin Cancer Res. 2008;14:6531–7. 41. Zheng C, Shen R, Li K, Zheng N, Zong Y, Ye D, et al. Epidermal growth factor receptor is overexpressed in neuroblastoma tissues and cells. Acta Biochim Biophys Sin. 2016;48:762–7. 42. Deng W, Shi B, He X, Zhang Z, Xu J, Li B, et al. Evolution and migration history of the Chinese population inferred from Chinese Y-chromosome evidence. J Hum Genet. 2004;49:339–48. 43. Shen P, Wang F, Underhill PA, Franco C, Yang WH, Roxas A, et al. Population genetic implications from sequence variation in four Y chromosome genes. Proc Natl Acad Sci U S A. 2000;97:7354–9. 44. Underhill PA, Shen P, Lin AA, Jin L, Passarino G, Yang WH, et al. Y chromosome sequence variation and the history of human populations. Nat Genet. 2000;26:358–61.

Journal

BMC CancerSpringer Journals

Published: Oct 3, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off